Excellent news for EGT Shareholders14 Apr 2025 07:31
Good morning,
I hope all is well. I am sharing the RNS released this morning on my appointment as Non-Executive Chairman, taking immediate effect: https://www.londonstockexchange.com/news-article/EGT/board-changes/16988364
I had intended to take this role last summer, following EGT’s admission onto AIM, however due to the recently announced news that I will be stepping down as Chairman on hVIVO, announced in hVIVO’s FY24 results, I now have more capacity to focus significantly on EGT.
I am very excited to take on this new role and I will look to replicate a similar route taken with hVIVO, in targeting acquisitions at an attractive rate to create a fast growing and profitable company.
As you may recall, when hVIVO kicked off this strategy, which was formally called Open Orphan plc in 2019, its share price was at 5p. Within two years, the share priced passed 47p, giving investors an excellent return on investment. I look to execute this strategy with EGT and over the next 12-18 months we hope to see EGT’s share price substantially appreciate through my highly successful buy-and-build strategy, taken with both hVIVO and Amryt Pharma.
We are aware of the public markets concern, following Trump’s tariff policies, which have created volatility across the board. At EGT I am confident that this uncertainty will create additional opportunities for the company to capitalise on and implement it’s M&A strategy.
Do let me know if you have any questions.
Kind regards,
Cathal Friel | Non-Executive Chairman |
Sign In
Follow the stocks
